Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism

The development of antitumor chemotherapy drugs remains a key goal for oncologists, and natural products provide a vast resource for anti-cancer drug discovery. In the current study, we found that the flavonoid dihydromyricetin (DHM) exhibited antitumor activity against liver cancer cells, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qingyu, Liu, Jie, Liu, Bin, Xia, Juan, Chen, Nianping, Chen, Xiaofeng, Cao, Yi, Zhang, Chen, Lu, CaiJie, Li, Mingyi, Zhu, Runzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982169/
https://www.ncbi.nlm.nih.gov/pubmed/24717393
http://dx.doi.org/10.1038/srep04628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982169/
https://www.ncbi.nlm.nih.gov/pubmed/24717393
http://dx.doi.org/10.1038/srep04628

Ejemplares similares